Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non‐small cell lung cancer with sensitive EGFR mutations-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non‐small cell lung cancer with sensitive EGFR mutations

Published:2021-01-25 Issue:3 Volume:14 Page:890-897
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clin Transl Sci

Author:

Zhang Yun¹,Wang Jing²,Yu Zhuang²,Ge Hong³,Zhang Lin‐Wei²,Feng Ling‐Xin²

Affiliation:

1. Department of Ultrasound the Affiliated Hospital of Qingdao University Qingdao Shandong China

2. Department of Oncology the Affiliated Hospital of Qingdao University Qingdao Shandong China

3. Department of Oncology People's Hospital of Rizhao Rizhao Shandong China

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.12951

Reference23 articles.

1. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

2. A systematic review of the characteristics associated with recall rates, detection rates and positive predictive values of computed tomography screening for lung cancer

3. The 2015 World Health Organization Classification of Lung Tumors

4. Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

5. A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ultrasensitive Response Explains the Benefit of Combination Chemotherapy Despite Drug Antagonism;Molecular Cancer Therapeutics;2024-03-25

2. Ultrasensitive response explains the benefit of combination chemotherapy despite drug antagonism;2023-02-27

3. Sequential chemotherapy and icotinib as first-line treatment for advanced epidermal growth factor receptor-mutated non-small cell lung cancer;World Journal of Clinical Cases;2022-06-26

4. Evaluating the Efficacy of EGFR-TKIs Combined With Radiotherapy in Advanced Lung Adenocarcinoma Patients With EGFR Mutation: A Retrospective Study;Technology in Cancer Research & Treatment;2022-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3